Abivax trading halt has been imposed on Euronext Paris from 9:00 a.m. CEST on 24 July 2025. This temporary suspension was initiated by the company to allow final confirmation of investor allocations and disclosure of pricing related to its public offering of American Depositary Shares (ADS) in the United States.
Each ADS corresponds to one ordinary share of Abivax, with a nominal value of €0.01. The halt is expected to be lifted at approximately 3:30 p.m. CEST on the same day, once the company issues a formal update.
Rationale for the Abivax trading halt
The Abivax trading halt supports a broader corporate strategy aimed at gaining access to deeper capital markets. By issuing ADS in the U.S., the biotechnology firm seeks to broaden its institutional investor base and secure capital to accelerate the clinical development of its lead candidate, obefazimod.
While the move is strategic, temporary trading halts can create short-term volatility. Moreover, shareholders should note the possibility of dilution following the ADS offering, depending on the final issue price and volume.
About Abivax
Abivax is a biopharmaceutical company operating in both France and the U.S., focused on therapies that modulate immune responses. Its flagship asset, obefazimod (ABX464), is currently in Phase 3 clinical development for patients with moderate to severe ulcerative colitis.
The firm continues to pursue innovations in treating chronic inflammatory conditions through its regulatory molecule platform, positioning itself as a leader in this therapeutic domain.
Trading expected to resume later today
Following this morning’s Abivax trading halt, the company will publish an official communication once allocation and pricing processes are concluded. Euronext Paris is expected to resume trading of Abivax ordinary shares around 3:30 p.m. CEST on 24 July 2025.
